3 treatment methods for high blood pressure, roughly between 1948 and 1960, coinciding with what has often been described as a 'golden age' of modern medicine, are the subject of this chapter. 6 I will explore how hypertension was transformed into a treatable disease when a new class of drugs, the ganglion blockers, moved from the laboratory to the bedside and eventually turned from experimental tools into routine treatment, by looking at the roles played by researchers in laboratories and clinics, and the debates over practical (and to some degree ethical) issues of the long-term administration of antihypertensive drugs. The sources from which I am reconstructing this story (mostly files from the archives of the Medical Research Council, hereafter MRC) also allow me some more general statements about the dynamics of biomedicine in Britain and the interactions between the public sector and the drug companies in this crucial period. The ganglion blockers are among the fruits of the MRC's intense campaign for the establishment of a new form of academic medicine in the country. Pharmaceutical companies, as we will see, initially played subordinate roles, while the MRC pulled the strings. 7 Whereas in the United States, as Nicolas Rasmussen has shown, drug companies actively approached and recruited medical academics, the story I will tell is one of 'shy' drug company representatives, recruited by the MRC for its plans. 8 Only in the mid-1950s, when consensus was emerging that some forms of hypertension benefited from long-term drug treatment, as Viviane
Quirke has shown for ICI, pharmaceutical companies became more proactive in the search for new antihypertensive drugs. 9 Hexamethonium and other ganglion blockers prepared this consensus. But the first responses to proposals to use hexamethonium as a routine drug were cautious, and I will demonstrate how important the development of an effective system for managing its effects, both desired and undesired, with nurse-technicians and patients playing important parts alongside clinicians, was for the successful transformation of the drug. This clinical setup for the treatment of high blood pressure with hexamethonium was devised, as we will see, by a British clinician with strong MRC links, but on the other side of the globe, in a teaching hospital in New Zealand. For the first stage of our journey following the ganglion blockers from the laboratory to the clinic, however, we are now turning to the physiology laboratories of Cambridge, England, and Cambridge, Massachusetts.
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Quaternary ammonium salts: From the physiology lab into the medicine cabinet
In the 1940s, the quaternary ammonium salts soon to be known as ganglion blockers were longstanding tools for physiological research. Pharmacologists and physiologists, notably the members of the Cambridge school of physiology had been interested in these drugs because some of their effects on experimental animals resembled those of the nerve poison curare. Their main focus of interest was not the clinical application of the drugs; they were studying the molecular mechanisms of the nervous system. The blood pressure lowering effect of some of these compounds, especially tetraethylammonium (TEA) had been noted on a few occasions by researchers, but none of them had seen it as particularly significant. 10 The name, ganglion blocking drugs, and the clinical potential of these compounds was a product of academic research on TEA by two young physiologists, George 12 Acheson and Moe initiated clinical tests for TEA, but they were not very successful. The effects of the drug did not last long enough and, while the tests established the notion of ganglion blockade as a possibility, TEA was not the drug that could move smoothly from bench to bedside. The first ganglion blockers that were to prove clinically useful were the methonium compounds, and for this part of the story we are now moving to Britain. As was the case for TEA, the observation that methonium compounds had an effect on blood pressure was partly a serendipitous discovery, a byproduct of work that had its roots in the Cambridge physiological-pharmacological tradition, combined with a heightened sensitivity for cardiovascular effects in the post-war years. however, as we will see later, depended on more than just understanding the mechanism of a drug. 16 Callow told Paton and his colleagues more about the chemical structure of lichenoformin, and they went upstairs to the NIMR's Chemistry Division under Harold King, where they obtained a range of substances with related chemical groups, in many of whom they found that they also released histamine and triggered a similar 'delayed repressor response'. Such responses had been observed before, but according to Paton 'it was entrancing to see this simple, specific response, to detect a coherent pattern emerging in the relationship between chemical structure and pharmacological response, and to see possible new approaches to the physiology of histamine.' 17 The series of compounds they tested also contained two derivatives of the methonium series, C8 and C16 (the figure stands for the number of atoms in the carbon chain between the two quaternary ammonium groups).
C8 produced a somewhat different, but also remarkably clean response. It proved to be a potent neuromuscular blocking agent, a drug that led to temporary paralysis, with potential applications for anaesthesia and surgery.
The decision to further pursue work on this group of substances was informed by the growing interest in developing synthetic drugs with curare-like action, to treat convulsions and as muscle relaxants for surgery. King had long been researching the active principle of curare. A significant factor was the arrival of Paton's co-worker, Eleanor Zaimis, who was experienced in chemistry as well as pharmacology. Encouraged by King, Paton and Zaimis decided to undertake a study of the whole series of methonium compounds and their effects, with carbon chain lengths from C2 to C12. Around the time when they started this work, Paton and Zaimis discovered that Ing and Barlow at Oxford were studying the same compounds, in a more systematic way and as one among a number of other 7 homologous series, in an attempt to establish the structure-action relationships of neuromuscular block. 18 In 1948, both groups arranged a simultaneous publication (as Letters to the Editor) in the journal Nature. It is noteworthy that effects on blood pressure were mentioned in neither paper. 19 Such effects had been noticed, however. Paton and his colleagues injected the drug into a number of laboratory animals, which revealed that C5 and C6, the compounds most active in anaesthetised cats, had significant effects on the animals' blood pressures. 20 Injected into a rabbit's ears, they made the 
Clinical trials and invisible industrialists
The MRC appointed Paton to chair an informal committee investigating possible clinical uses of the methonium drugs. 24 Along with Frank Green, the Council's Chief Medical Officer, Paton was the main correspondent in all matters concerning clinical uses of the methonium compounds (he also prepared the official report on the drugs). 25 Not long after Paton and Zaimis heroically tested the effects of several methonium compounds on themselves at Westminster Hospital, together with the anaesthetist Geoffrey Organe, the MRC initiated the first clinical study of pentamethonium for the treatment of hypertension. 26 The Lancet published the results in August 1948. 27 The investigation was carried out, 'at and that 'an excessive fall in blood-pressure has been the only serious toxic effect so far observed'.
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Anaesthetists experimented with hexamethonium as an antidote to the muscle relaxant decamethonium and viewed blood pressure reduction as an undesired side effect: 'In the very first case it seemed that the ensuing hypotension might be severe enough to be fatal.' 30 It is not obvious from these early publications that soon the lowering of blood pressure would be discussed as the main rather than a The initial responses to the methonium compounds and the suggestion that they might provide a useful treatment option for high blood pressure were cautious. Increasingly, though, they were patients) that 'hexamethonium seems to provide a useful method of reducing the blood pressure in severe hypertension with ready administration and relative freedom from toxicity'. 35 The main problem was finding the right dosage, and some of the side effects were quite drastic, too. R. Turner in Edinburgh suggested that 'methonium drugs have as yet no place in the routine management of patients, though they may prove useful in the treatment of resistant symptoms related to hypertension.
We need more information about their precise action, and for the present it will be most profitable to study, in detail, patients who might otherwise be treated by sympathectomy.' 36 These clinical studies on the methonium compounds were initiated by the MRC and not, as we would expect today and as even some insiders assumed, by the pharmaceutical industry. there is no obligation on Kay and Smith to assist Geigy with advice unless they like to do so. 40 The power relationships, it seems, were distinctly different from those that Nick Rasmussen has described for the United States, where he finds patterns of company-funded clinical research very similar to today's as early as the inter-war period.
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Therapeutic enthusiasm
Although the MRC sought to promote the ganglion blockers, the initial responses from clinicians involved in the early clinical trials were cautious. In order to understand the transformation of hexamethonium from experimental drug to routine treatment for malignant hypertension, in this section we will look at the role of clinicians such as Frederick Horace Smirk, who we might want to call 'therapeutic enthusiasts'. 42 including pharmaceutical companies. This success was undoubtedly due to his great enthusiasm for pharmaceutical solutions and his success in turning the ganglion blockers into routine drugs. He is also credited with the development, by selective inbreeding, of laboratory rats with inherited hypertension. 47 The greatest coup of his career as research administrator, however, was to secure £120,000 from the Initially, however, the war years did not make it easy to establish a functioning laboratory in
Dunedin. There was hardly any equipment and much had to be improvised, supplies were unreliable, and there was not much space for Smirk and his staff. of their experiments with pentamethonium and hexamethonium in humans. 48 Smirk, who received supplies of the drugs from May and Baker when he returned to New Zealand, it seems, had found the compounds he was looking for.
An important problem of the methonium compounds which accounted for much of the scepticism by clinicians who had tested them was their low solubility in water and the resulting low (and unreliable) rate with which the drugs were absorbed into the bloodstream when taken by mouth. clinic, look at the data, and order the appropriate afternoon doses. Patients would attend daily until the correct dose had been attained and would then be allowed to leave, having been supplied with tuberculin syringes, needles, and multidose containers of the drug, which they had been trained to use. 50 The multidose containers had been prepared at the university's pharmacology department by dissolving bulk supplies provided by May and Baker. Some years later, such multidose vials were available prepacked, directly from the drug producers.
Drugs and discipline
Hexamethonium, it seems, disciplined doctors, patients, carers, and technicians alike. 'It is most important', Smirk stated in his account of the practices in the hypertension clinic, 'that the patient should understand something of the working of the drug, and in our experience the technician is invaluable in educating patients, and any special points she cannot answer can be dealt with when the doctor comes round'. 51 52 Smirk devised a treatment manual for patients and carers that explained the reasons for the treatment, suggested ways of dealing with the possible side effects of the drugs, which would disappear soon if patients co-operated and played active parts in the therapy, and warned of the possible consequences of non-compliance or interruption of the treatment. 53 Smirk explained patients that '[t]he object of treatment is to decrease the risk of complications of high blood pressure such as heart failure and stroke, and secondly to relieve symptoms such as headache and breathlessness in cases where these are due to high blood pressure'. 54 Patients were encouraged to perform simple tests on themselves, which relied on them developing an awareness of the effects of the drug on their bodies. The 'standing test' took advantage of one of the most common side effects of hexamethonium, postural hypotension, a sudden lowering of the blood pressure when patients stood up, which led to dizziness. 'Almost all of our well-trained patients can tell the doctor from their own subjective sensations whether a given dose is producing a considerable fall of the blood pressure', as Smirk reports. 'Intelligent and co-operative patients have been entrusted with the fine adjustment of their dose'. 55 The ways in which Smirk's practices dealt with postural hypotension and even made use of this side effect, even more than the issue of resorption, indicate that even a difficult drug could be managed. as Green wrote in a letter to Paton, on '"faulty technique", namely lack of proper ancillary care of the patients'. 56 Smirk's practices involved patients as well as technicians and nurses in active and responsible roles. Tending to the psychology of the patients was part of the regime: 'It is well to remember that nervous tension, worry, quarrels, excitement and adverse emotion lead to elevation of the blood pressure', Smirk wrote. 'It is a part of treatment to lessen such troubles.' 57 How was this done? 'Reassurance by doctor and technician that the milder side effects are in no sense dangerous and will probably disappear anyhow usually leads to a happier frame of mind.' 58 As important, it seems, was the company of other patients. Patients would sit together in groups of four while undergoing their lengthy tests, exchanging experiences, and there was 'something of the atmosphere of a club about the clinic'. 59 Not all were happy, though: 'It is well to realise … that a drug which, in a proportion of patients, causes side effects will get the blame for all sorts of incidental illness.' 60 Frank Green, after his visit in New Zealand, reported to Paton:
I talked to some of his patients under treatment in the wards, and I think it is fair to say that I got the impression that their enthusiasm for hexamethonium therapy is not quite so great as his.
Not unnaturally, they dislike the side effects. If, however, as Smirk says, it is possible to keep patients with malignant hypertension alive and reasonably comfortable for periods at least of several years, then that does represent an important advance in therapy. 61 To be fair, though, the patients who Green met were most likely newly admitted patients who had not yet been 'trained'.
Conclusion
A Lancet editorial in 1951 supports Green's conclusions, stating that: 'Early reports leave no doubt that the methonium compounds are the most powerful hypotensive agents yet developed.' 62 Other therapeutic enthusiasts, like Edward Freis were quick to acknowledge this. 63 By the end of the 1950s, hypertension was transformed into a treatable disease. The ganglion blockers, along with the routines designed by Smirk and his colleagues, had come to form a relatively standardized package that circulated easily and that paved the way for new, more specific antihypertensive drugs. Drug therapy for hypertension had returned from the more remote parts of the British Empire to the metropolis.
Green and Paton felt that the MRC had done what it could do for the methonium compounds in 1952, when they felt that these drugs no longer needed boosting. 64 Their emphasis was clearly on research rather than commercial exploitation; for the Council hexamethonium was part of a long-standing campaign to establish their concept of biomedicine as the dominant form of medical research in Britain, in the clinic as well as the preclinical sciences. Commercial exploitation followed, however, with several drug companies developing their own, patent-protected ganglion blockers on the back of the success with the methonium compounds. Examples are May and Baker's Gaplegin, or Pendiomide, which was developed and marketed by both Ciba and ICI more or less simultaneously. The new ganglion blockers were not necessarily better antihypertensives than hexamethonium, but they were more easily absorbed by the gut and therefore more reliable when taken by mouth, and therefore disposed with the need for elaborate clinical setups like that developed by Smirk. 65 For several producers, the ganglion blockers provided stepping stones into the new field of pharmaceuticals for blood pressure control. 66 Modern drug research, we assume, aims to find drugs for specific targets. In the case of was not what it is today. Malignant hypertension, seriously increased blood pressure which led to lifethreatening, pathological changes, today has more or less disappeared from the industrialised world.
Starting with the ganglion blockers, new drugs turned hypertension from an acute into a chronic disease that could be managed (rather than cured) and allowed sufferers to lead reasonably normal lives (in a way that was similar to the role that insulin played for diabetic patients). But more than that, the ganglion blockers paved the way for a new therapeutic enthusiasm. In the case of hypertension it has become acceptable, even recommended, to treat a symptom-less physiological phenomenon, as if it were a disease.
